CA2131729A1 - Helicobacter pylori proteins useful for vaccines and diagnostics - Google Patents

Helicobacter pylori proteins useful for vaccines and diagnostics

Info

Publication number
CA2131729A1
CA2131729A1 CA002131729A CA2131729A CA2131729A1 CA 2131729 A1 CA2131729 A1 CA 2131729A1 CA 002131729 A CA002131729 A CA 002131729A CA 2131729 A CA2131729 A CA 2131729A CA 2131729 A1 CA2131729 A1 CA 2131729A1
Authority
CA
Canada
Prior art keywords
proteins
helicobacter pylori
pylori
vaccines
diagnostics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002131729A
Other languages
French (fr)
Other versions
CA2131729C (en
Inventor
Antonello Covacci
Massimo Bugnoli
John Telford
Giovanni Macchia
Rino Rappuoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITFI920052A external-priority patent/IT1262895B/en
Application filed by Individual filed Critical Individual
Priority to CA002383007A priority Critical patent/CA2383007A1/en
Publication of CA2131729A1 publication Critical patent/CA2131729A1/en
Application granted granted Critical
Publication of CA2131729C publication Critical patent/CA2131729C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Abstract

Helicobacter pylori is known to cause or be a cofactor in type B gastritis, peptic ulcers, and gastric tumors. In both deve-loped and developing countries, a high percentage of people are infected with this bacterium. The present invention relates gen-erally to certain H. pylori proteins, to the genes which express these proteins, and to the use of these proteins for diagnostic and vaccine applications. Specifically, molecular cloning, nucleotide, and amino acid sequences for the H. pylori cytotoxin (CT), the "Cytotoxin Associated Immunodominant" (CAI) antigen, and the heat shock protein (hsp60) are described herein.
CA002131729A 1992-03-02 1993-03-02 Helicobacter pylori proteins useful for vaccines and diagnostics Expired - Lifetime CA2131729C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002383007A CA2383007A1 (en) 1992-03-02 1993-03-02 Helicobacter pylori proteins useful for vaccines and diagnostics

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITFI920052A IT1262895B (en) 1992-03-02 1992-03-02 Protein extracted from cytotoxic strains of Helicobacter pylori, gene expressing it, use of the protein as a vaccine or for diagnostic purposes.
ITFI92A000052 1992-03-02
WOPCT/EP93/00158 1993-01-25
EPPCT/EP93/00158 1993-01-25
PCT/EP1993/000472 WO1993018150A1 (en) 1992-03-02 1993-03-02 Helicobacter pylori proteins useful for vaccines and diagnostics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002383007A Division CA2383007A1 (en) 1992-03-02 1993-03-02 Helicobacter pylori proteins useful for vaccines and diagnostics

Publications (2)

Publication Number Publication Date
CA2131729A1 true CA2131729A1 (en) 1993-09-16
CA2131729C CA2131729C (en) 2008-02-12

Family

ID=26069992

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002383007A Pending CA2383007A1 (en) 1992-03-02 1993-03-02 Helicobacter pylori proteins useful for vaccines and diagnostics
CA002131729A Expired - Lifetime CA2131729C (en) 1992-03-02 1993-03-02 Helicobacter pylori proteins useful for vaccines and diagnostics

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002383007A Pending CA2383007A1 (en) 1992-03-02 1993-03-02 Helicobacter pylori proteins useful for vaccines and diagnostics

Country Status (7)

Country Link
US (3) US6077706A (en)
EP (1) EP0967279B1 (en)
JP (4) JP3368902B2 (en)
AU (1) AU3630093A (en)
CA (2) CA2383007A1 (en)
DE (2) DE69334197T2 (en)
WO (1) WO1993018150A1 (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866375A (en) * 1991-10-31 1999-02-02 Chiron S.P.A. Method for the culture of microorganisms of the genera helicobacter, campylobacter and arcobacter employing culture media comprising cyclodextrins
WO1993016723A1 (en) * 1992-02-26 1993-09-02 Vanderbilt University Purified vacuolating toxin from helicobacter pylori and methods to use same
US5721349A (en) * 1992-02-26 1998-02-24 Vanderbilt University Vacuolating toxin-deficient H. pylori
US5928865A (en) * 1992-03-02 1999-07-27 Chiron S.P.A. Compositions comprising isolated Helicobacter pylori CagI polynucleotides and method of preparation thereof
IT1262896B (en) * 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
MX9301706A (en) * 1992-04-13 1994-05-31 Oravax Inc VACCINE COMPOSITION FOR THE TREATMENT OF HELICOBACTER INFECTION.
US5403924A (en) * 1992-10-13 1995-04-04 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
JPH08509873A (en) * 1993-05-19 1996-10-22 アンスティテュ・パストゥール Immune composition against Helicobacter infection, polypeptide used in the composition and nucleic acid sequence encoding the polypeptide
US6258359B1 (en) 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
GB9313279D0 (en) * 1993-06-28 1993-08-11 Medical Res Council Protection against infection with helicobacter pylori
WO1995003824A1 (en) * 1993-07-27 1995-02-09 Csl Limited Treatment of h. pylori associated gastroduodenal disease
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
GB2290710B (en) * 1994-06-29 1998-03-25 Reckitt & Colmann Prod Ltd Protease from helicobacter pylori for use in vaccines/therapeutic compositions
EP0769018B1 (en) * 1994-07-01 2002-12-18 Chiron Corporation Helicobacter proteins and vaccines
GB9505438D0 (en) * 1995-03-17 1995-05-03 Sod Conseils Rech Applic Antisense oligonucleotides
WO1997003359A1 (en) * 1995-07-07 1997-01-30 Oravax, Inc. Helicobacter clpb
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
JPH11502418A (en) * 1995-10-09 1999-03-02 パストゥール メリユ セリュム エ ヴァサン Helicobacter lactoferrin receptor
EP0909323B1 (en) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
JPH1033179A (en) * 1996-07-24 1998-02-10 Fuso Yakuhin Kogyo Kk Probe for diagnosis of infectious disease
WO1998012562A1 (en) * 1996-09-20 1998-03-26 Cortecs International Limited Adhesins from heliobacter pylori and their diagnostic and therapeutic uses
PT946874E (en) * 1996-12-19 2002-10-31 Chiron Corp HELICOBACTER PYLORI DIAGNOSIS
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
CN1254292A (en) * 1997-04-30 2000-05-24 梅里厄奥拉瓦克斯公司 Anti-helicobacter vaccine composition for use by subdiahragmatic systemic route, and combined mucosal/parenteral immunization method
FR2748477B1 (en) * 1997-07-01 2001-07-13 Pasteur Merieux Serums Vacc NEW MEMBRANE PROTEIN OF HELICOBACTER PYLORI
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
JP2002508156A (en) * 1997-12-31 2002-03-19 ストレスジェン バイオテクノロジーズ コーポレイション Streptococcus heat shock proteins of the Hsp60 family
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
US6841155B1 (en) 1998-04-30 2005-01-11 Chiron S.R.L. Immunization against and treatment for infection by H. pylori
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
GB9924060D0 (en) * 1999-10-11 1999-12-15 Chiron Spa VIP54 protein
CN1796404A (en) * 1999-10-29 2006-07-05 启龙有限公司 Neisserial antigenic peptides
MXPA02006962A (en) 2000-01-17 2002-12-13 Chiron Spa Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins.
AU6669401A (en) 2000-06-02 2001-12-11 Univ Connecticut Health Ct Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
DE60236864D1 (en) 2001-05-31 2010-08-12 Novartis Vaccines & Diagnostic CHIMERIC ALPHAVIRUS REPLICANT PARTICLES
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
JP4384489B2 (en) 2001-08-20 2009-12-16 ユニバーシティー オブ コネティカット ヘルス センター Method for preparing a composition comprising a heat shock protein or α-2-macroglobulin useful for the treatment of cancer and infectious diseases
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
WO2004012751A1 (en) * 2002-08-02 2004-02-12 Sumitomo Pharmaceuticals Company, Limited Bacterial cell wall skeleton component preparaion
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ATE352316T1 (en) 2002-11-01 2007-02-15 Glaxosmithkline Biolog Sa IMMUNOGENIC COMPOSITION
AU2003288660A1 (en) 2002-11-15 2004-06-15 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US8034378B2 (en) 2002-12-27 2011-10-11 Novartis Vaccines And Diagnostics, Inc Immunogenic compositions containing phospholipid
ES2423800T3 (en) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Use of organic compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
EP2179729B1 (en) 2003-06-02 2016-07-20 GlaxoSmithKline Biologicals SA Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
JP4522997B2 (en) 2003-08-13 2010-08-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Improved method for purifying TFPI and TFPI analogs
US7892557B2 (en) 2004-02-19 2011-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peptide mimotopes of mycobacterial mannosylated lipoglycans and uses thereof
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
WO2006001011A1 (en) 2004-06-24 2006-01-05 Yissum Research Development Company Use of mycobacterial mannosylated lipoglycans peptide mimotopes for treating inflammation
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
WO2006069198A1 (en) 2004-12-22 2006-06-29 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
EP2357000A1 (en) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
ATE539079T1 (en) 2006-03-23 2012-01-15 Novartis Ag IMIDAZOCHINOXALINE COMPOUNDS AS IMMUNE MODULATORS
KR100846494B1 (en) * 2006-09-26 2008-07-17 삼성전자주식회사 Primer set for amplifying target sequences of Helicobacter pylori method for detecting Helicobacter pylori using the primer set and kit for detecting Helicobacter pylori comprising the primer set
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
ES2561483T3 (en) 2007-09-12 2016-02-26 Glaxosmithkline Biologicals Sa GAS57 mutant antigens and GAS57 antibodies
BRPI0821240B8 (en) 2007-12-21 2022-10-04 Novartis Ag mutant forms of streptolysin o
AU2009276357B2 (en) 2008-08-01 2014-09-11 Cleveland Biolabs, Inc. Methods for treating reperfusion injuries
EP2331127A2 (en) 2008-09-18 2011-06-15 Novartis AG Vaccine adjuvant combinations
NZ594029A (en) 2009-01-12 2014-01-31 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
BR112012004276A2 (en) 2009-08-27 2017-10-24 Novartis Ag adjuvant comprising aluminum, oligonucleotide and polycation
DK2459216T3 (en) 2009-09-02 2013-12-09 Novartis Ag IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS
EP2575988A1 (en) 2010-05-28 2013-04-10 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
EA201390341A1 (en) 2010-09-01 2013-08-30 Новартис Аг ADSORPTION OF IMMUNOTE POTENTIATORS ON INSOLUBLE SALTS OF METALS
EP2652511B8 (en) 2010-12-14 2017-06-28 GlaxoSmithKline Biologicals SA Flow cytometry analysis of materials adsorbed to metal salts
BR112013017283A2 (en) 2011-01-10 2016-10-25 Cleveland Biolabs Inc use of toll-like receptor agonist for cancer treatment
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
SI2822947T1 (en) 2012-03-07 2016-10-28 Glaxosmithkline Biologicals S.A. Arginine salts of a tlr7 agonist
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
JP6345603B2 (en) 2012-03-08 2018-06-20 ノバルティス アーゲー Adjuvanted formulation of booster vaccine
EP2877852B1 (en) * 2012-07-23 2022-05-25 Hermouet, Sylvie A protein microarray for characterizing the specificity of the monoclonal immunoglobulins of mgus or myeloma patients
US10202426B2 (en) 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses
EP3206708B1 (en) 2014-10-16 2022-11-02 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
SE541618C2 (en) 2017-02-24 2019-11-12 Biotome Pty Ltd Novel peptides and their use in diagnosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005943A1 (en) 1986-03-28 1987-10-08 Board Of Trustees Of University Of Illinois Compositions and methods for clones containing dna sequences associated with multidrug resistance in human cells
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5459041A (en) * 1988-02-18 1995-10-17 Enteric Research Laboratories, Inc. Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection
US4882271A (en) * 1988-03-10 1989-11-21 Baylor College Of Medicine Process for preparation of high molecular weight cell-associated protein of campylobacter pylori and use for serological detection of campylobacter pylori infection
FR2637612B1 (en) * 1988-10-06 1993-09-10 Pasteur Institut NUCLEOTIDE SEQUENCES ENCODING A PROTEIN WITH UREASIC ACTIVITY
AU640118B2 (en) 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
GB8928625D0 (en) * 1989-12-19 1990-02-21 3I Res Expl Ltd H.pylori dna probes
US5292658A (en) * 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
DE69223562T2 (en) * 1991-08-27 1998-06-04 Hoffmann La Roche Methods and reagents for the detection of hepatitis C.
US5354854A (en) * 1991-11-07 1994-10-11 The Curators Of The University Of Missouri Expression system for use in plants to suppress foreign expression and method
US5721349A (en) * 1992-02-26 1998-02-24 Vanderbilt University Vacuolating toxin-deficient H. pylori
IT1262895B (en) * 1992-03-02 1996-07-22 Protein extracted from cytotoxic strains of Helicobacter pylori, gene expressing it, use of the protein as a vaccine or for diagnostic purposes.
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US5403924A (en) * 1992-10-13 1995-04-04 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6902903B1 (en) * 1996-12-19 2005-06-07 Chiron Corporation Helicobacter pylori diagnostics
ES2276788T3 (en) * 2000-05-10 2007-07-01 Sanofi Pasteur Limited IMMUNOGEN POLIPEPTIDES CODED BY MAGE MINIGENS AND THEIR USES.

Also Published As

Publication number Publication date
JPH07504565A (en) 1995-05-25
US7700755B2 (en) 2010-04-20
JP3368902B2 (en) 2003-01-20
US6077706A (en) 2000-06-20
US20050276819A1 (en) 2005-12-15
DE69333110D1 (en) 2003-08-28
JP2006055168A (en) 2006-03-02
AU3630093A (en) 1993-10-05
CA2131729C (en) 2008-02-12
CA2383007A1 (en) 1993-09-16
US20040048353A1 (en) 2004-03-11
JP2000350591A (en) 2000-12-19
DE69334197T2 (en) 2008-12-11
EP0967279A1 (en) 1999-12-29
JP3408494B2 (en) 2003-05-19
DE69333110T2 (en) 2004-05-06
JP2000333686A (en) 2000-12-05
DE69334197D1 (en) 2008-02-14
WO1993018150A1 (en) 1993-09-16
EP0967279B1 (en) 2008-01-02

Similar Documents

Publication Publication Date Title
CA2131729A1 (en) Helicobacter pylori proteins useful for vaccines and diagnostics
NO20070618L (en) Compounds and Methods for Immunotherapy and Diagnosis of Tuberculosis.
MY119003A (en) Bacterial antigens and vaccine compositions
SG48353A1 (en) Helicobacter pylori proteins useful for vaccines and diagnostics
EP2168596A3 (en) Immunisation against chlamydia trachomatis
HK1080506A1 (en) Fusion proteins of mycobacterium tuberculosis
AU2001276619A1 (en) Immunisation against chlamydia pneumoniae
EA007409B1 (en) Streptococcus antigen polypeptides, methods of producing and use thereof
WO1995029193A3 (en) Melanoma antigens
US20090035259A1 (en) Group a streptococcal vaccines
BR9906927A (en) Neisseria meningitidis proteins
AU4545889A (en) Synthetic dna derived recombinant hiv antigens
NO883763L (en) THERAPEUTIC MIXTURES AGAINST STRIPTOCOCCIN INFECTIONS, TRANSFORMED HOSTS, IMMUNIZATION PROCEDURES, AND REPLACEMENT PRODUCTS.
AU2191597A (en) Vmp-like sequences of pathogenic borrelia
HU9401511D0 (en) Vaccine against streptococcus suls infection
KR970703165A (en) Vaccine against mycobacterial infection (VACCINE AGAINST MYCOBACTERIAL INFECTIONS)
AU9388498A (en) Group a streptococcal vaccines
DK0892054T3 (en) Clostridium perfringens vaccine
AU2667600A (en) Identification of specific differentially expressed antigens
NZ512448A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1801217A1 (en) Group A streptococcal vaccines
EP1009764A1 (en) VACCINE COMPOSITIONS COMPRISING THE $i(HELICOBACTER PYLORI) FlgE POLYPEPTIDE
NZ512308A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
EP0949333A4 (en) Mutant measles virus antigens and genes encoding the same
MXPA99011528A (en) Vaccine compositions comprising the helicobacter pylori

Legal Events

Date Code Title Description
EEER Examination request